Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for prevention of intestinal acute graft-versus-host disease after allogeneic stem cell transplantation
2018-002141-11Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Vedolizumab + background aGvHD prophylaxis with Placebo + background aGvHD prophylaxis (2 arms). Primary endpoint: Intestinal acute graft-versus-host disease-free survival by Day +180. Started Sep 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2018-002141-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002141-11.